Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sarepta Therapeutics Inc    SRPT

SAREPTA THERAPEUTICS INC (SRPT)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sarepta Therapeutics Inc : SRPT, FB, CRUS and OMER added to NASDAQ Active Stock Watch List at GSR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/24/2013 | 03:05pm CEST

New York, NY - (ACCESSWIRE) - 09/24/2013 - Growing Stock Report initiates its NASDAQ Active Stock Watch List adding Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Facebook, Inc. (NASDAQ:FB), Cirrus Logic Inc. (NASDAQ:CRUS), and Omeros Corporation (NASDAQ:OMER)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) a biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases closed up in its previous session (+10.79%) on 6,581,320 shares traded after Sarepta was upgraded to Overweight from Neutral at Piper Jaffray. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is currently up (+251.61%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=SRPT&SubId=AW

Facebook, Inc. (NASDAQ:FB) operates as a social networking company worldwide closed down in its previous session (-0.63%) on 75,274,915 shares traded after Facebook Quietly Rolls Out Its Mobile Payments Autofill Product, AllThingsD Reported. Facebook, Inc. (NASDAQ:FB) is currently down (-2.75%) from its recent 52-week high, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Facebook, Inc. (NASDAQ:FB)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=FB&SubId=AW

Cirrus Logic Inc. (NASDAQ:CRUS) a fabless semiconductor company that develops analog and mixed-signal integrated circuits for a range of consumer and industrial markets closed up in its previous session (+5.41%) on 6,219,309 shares traded after CIRRUS LOGIC INC Filed SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year. Cirrus Logic Inc. (NASDAQ:CRUS) is currently up (+46.96%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Cirrus Logic Inc. (NASDAQ:CRUS)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=CRUS&SubId=AW

Omeros Corporation (NASDAQ:OMER) a clinical-stage biopharmaceutical company that engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system closed up in its previous session (+28.21%) on 8,095,031 shares traded after Omeros has been Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference on Friday, September 27, 2013. Omeros Corporation (NASDAQ:OMER) is currently up (+167.95%) from its recent 52-week low, which has prompted Growing Stock Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Omeros Corporation (NASDAQ:OMER)

Click Here: http://www.growingstockreport.com/Survey.aspx?stock=OMER&SubId=AW

GrowingStockReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals GrowingStockReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.GrowingStockReport.com

Disclosure: GrowingStockReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit GrowingStockReport.com website, for complete risks and disclosures.

Contact Info:
Growing Stock Report
[email protected]


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SAREPTA THERAPEUTICS INC
04/23Sarepta Therapeutics to Announce First Quarter 2018 Financial Results and Rec..
GL
04/18SAREPTA THERAPEUTICS : How BTCY Could Look a Lot Like SRPT in a Year's Time
AQ
04/04SAREPTA THERAPEUTICS : Announces Inducement Grants Under Nasdaq Listing Rule 563..
AQ
03/31Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 56..
GL
03/29SAREPTA THERAPEUTICS : Patent Issued for Boronic Acid Conjugates of Oligonucleot..
AQ
03/23SAREPTA THERAPEUTICS : U.S. Patents Awarded to Inventors in Washington (March 23..
AQ
03/23SAREPTA THERAPEUTICS : Announces Launch of Route 79, the Duchenne Scholarship Pr..
AQ
03/21SAREPTA THERAPEUTICS : Announces Launch of Route 79, The Duchenne Scholarship Pr..
AQ
03/20Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship P..
GL
03/16SAREPTA THERAPEUTICS : Announces Plan to Submit a New Drug Application for Accel..
AQ
More news
News from SeekingAlpha
04/26BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Takeda Raises Shire Bid, Daiichi Fails DM.. 
04/16Pfizer's DMD Drug Could Spell Long Term Trouble For Sarepta 
04/13Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned 
04/12Dosing underway in early-stage study of Pfizer DMD candidate 
04/03SAREPTA : Riskier Than The Market Thinks 
Financials ($)
Sales 2018 305 M
EBIT 2018 -75,6 M
Net income 2018 -74,5 M
Finance 2018 534 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 152,13
EV / Sales 2018 14,5x
EV / Sales 2019 9,08x
Capitalization 4 964 M
Chart SAREPTA THERAPEUTICS INC
Duration : Period :
Sarepta Therapeutics Inc Technical Analysis Chart | SRPT | US8036071004 | 4-Traders
Technical analysis trends SAREPTA THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 88,5 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Douglas S. Ingram President, Chief Executive Officer & Director
M. Kathleen Behrens Chairman
Sandesh Mahatme Executive VP, Chief Financial & Business Officer
Catherine Stehman Breen Chief Medical Officer
Guriqbal S. Basi Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
SAREPTA THERAPEUTICS INC39.83%4 964
GILEAD SCIENCES1.51%94 816
VERTEX PHARMACEUTICALS3.88%39 523
REGENERON PHARMACEUTICALS-17.01%33 601
GENMAB18.71%12 384
BEIGENE LTD (ADR)69.87%9 095